Adverse effects of using dolutegravir HIV in pregnant women and their newborn

Joint Webinar on 7^th International Conference on Global Healthcare & 4^th International Conference on Addiction Research and Therapy

October 08, 2021 | Webinar

Mahecha Reyes Eduardo

TLI Foundation, USA

Posters & Accepted Abstracts: J Nurs Res Pract

Abstract :

Introduction: The adverse effects of dolutegravir on the mother and the fetus not yet have been widely studied; the integrate inhibitor antiretroviral drug was to prevent vertical transmission of HIV. Objective: To identify the adverse effects of the use of dolutegravir that have occurred in HIV-positive pregnant women and their children. Methodology: A scoping review we performed in the medline, cochrane library and EBSCO databases, with the MeSH terms dolutegravir and pregnancy. Eligibility criteria: Clinical trials and observational studies conducted in pregnant women with HIV were treated with dolutegravir included. The search was limited to articles in inglés and spanish and published Until September 1 2018. Results: The bibliographic search obtained seven investigations. Two studies report mild adverse effects in the mother. Six studies related to pregnancy outcomes described and delivery, with preterm delivery and small for age stational being the most reported. Four cases of neural tube defects in four studies we reported. Discussion: There is not enough scientific evidence to associate the use of dolutegravir with the appearance of adverse effects on the mother and her children.